GlassScriptPhysician profile
Casey R Benton
NPI 1619291531
$3,951.83
in general payments reported to CMS, 2019-2025
28 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $162 · 2021: $370 · 2022: $490 · 2023: $715 · 2024: $975 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $572.73 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $543.18 | 2019-2025 | |
| Pfizer INC. | $515.10 | 2019-2024 | |
| Amgen INC. | $377.06 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $236.31 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.86 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $193.48 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $156.74 | 2020-2024 | Mitraclip |
| Esperion Therapeutics, INC. | $152.70 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $132.17 | 2021-2024 | Verquvo |
| Abiomed | $103.65 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $91.29 | 2019-2025 | Farxiga, Brilinta |
| Scpharmaceuticals INC. | $88.80 | 2023-2025 | |
| Boston Scientific Corporation | $71.32 | 2024 | Watchman Access System, Vigilant X4 Crt-D |
| Kowa Pharmaceuticals America, INC. | $70.03 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $61.45 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.27 | 2019 | |
| Novo Nordisk INC | $55.38 | 2024-2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $52.56 | 2024 | Arcalyst |
| Sanofi US Services INC. | $36.19 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $25.12 | 2024 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.70 | 2023-2025 | Lifevest |
| Innovation Technologies INC | $23.78 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.10 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $17.62 | 2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $15.72 | 2020 | |
| Gilead Sciences, INC. | $14.54 | 2019 | |
| Tactile Systems Technology INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.